Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (GB:0VQA)
LSE:0VQA
Holding GB:0VQA?
Track your performance easily
0VQA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.88 - $99.30
Previous Close$64.29
Volume4.76K
Average Volume (3M)10.92K
Market Cap
$6.99B
Enterprise Value$6.05B
Total Cash (Recent Filing)$942.26M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta3.12
Next Earnings
Oct 30, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding110,796,200
10 Day Avg. Volume14,691
30 Day Avg. Volume10,924
Standard Deviation0.38
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)8.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-60.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-382.16
Forecast
1Y Price Target
$109.90Price Target Upside70.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Investor SentimentInvestor sentiment has been very favorable on the back of data readouts in the GLP-1 space, and similar enthusiasm is expected on VKTX’s readout.
Market PotentialThe market for GLP-1s is expected to be substantial, with orals playing an increasingly important role.
Safety And TolerabilityVK2735 program shows lower rates of gastrointestinal adverse events (GI AEs) compared to other obesity treatments.
Bears Say
Drug Efficacy And TolerabilityInitial fear was likely overblown as its weight loss efficacy was not that scary as QD and the tolerability on BID may not be optimal.
Drug Side EffectsRoche's CT-388 program shows high rates of nausea, diarrhea, vomiting, and constipation, which may limit its dose optimization.
Stock PerformanceThe stock is trading down ~10% although the data is positive and compares favorably to Rezdiffra (resmetirom).
---
Options Prices
Currently, No data available
---
Ownership Overview
8.85% Insiders
30.59% Mutual Funds
31.03% Other Institutional Investors
29.54% Public Companies and
Individual Investors
0VQA FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest share price was $8.88 and its highest was $99.30 in the past 12 months.
What is Viking Therapeutics’s market cap?
Currently, no data Available
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 30, 2024 which is in 33 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 24, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.063.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -$0.24.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 110,796,200 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went up 28.757%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 72M.
---
Viking Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.90 (70.94% Upside)
$109.90 (70.94% Upside)
Blogger Sentiment
Bullish
GB:0VQA Sentiment 97%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $8.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
441.19%
12-Months-Change
Fundamentals
Return on Equity
-14.80%
Trailing 12-Months
Asset Growth
136.30%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
0VQA Earnings Call
Q2 2024
0:00 / 0:00
---
0VQA Stock 12 Month Forecast
Average Price Target
$109.90
▲(70.94% Upside)
Technical Analysis
Viking Therapeutics
―
Aptose Biosciences
―
Longeveron
―
Corvus Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering 0VQA
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+216.19%
reiterated a buy rating 2 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +216.19% per trade.
---